Doxycycline stabilizes vulnerable plaque via inhibiting matrix metalloproteinases and attenuating inflammation in rabbits

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Dong, Mei ^a   Zhong, Lin ^b   Chen, Wen Qiang ^a   Ji, Xiao Ping ^a   Zhang, Mei ^a   Zhao, Yu Xia ^a   Li, Li ^a   Yao, Gui Hua ^a   Zhang, Peng Fei ^a   Zhang, Cheng ^a   Zhang, Lei ^a   Zhang, Yun ^a  

^a SHANDONG UNIVERSITY   (China)

^b YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; DOXYCYCLINE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; SIMVASTATIN; STROMELYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BIOCHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; ECHOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPID BLOOD LEVEL; MALE; NONHUMAN; PATHOLOGY; PROTEIN EXPRESSION; RABBIT; SEROLOGY; THICKNESS; UPREGULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AORTA, ABDOMINAL; DOXYCYCLINE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPIDS; MALE; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; PLAQUE, ATHEROSCLEROTIC; RABBITS; RNA, MESSENGER; ULTRASONOGRAPHY;

EID: 84862652348     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039695     Document Type: Article

References (24)

1. Ross R, (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340 (2): 115-126.
2. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, et al. (2003) From vulnerable plaque to vulnerable patient. A call for new definition and risk assessment strategies: part I. Circulation 108 (14): 1664-1672.
3. Sukhova GK, Schönbeck U, Rabkin E, Schoen FJ, Poole AR, et al. (1999) Evidence for increased collagenolysis by interstitial collagenases-1 and-3 in vulnerable human atheromatous plaques. Circulation 99 (19): 2503-2509.
4. Johnson JL, Devel L, Czarny B, George SJ, Jackson CL, et al. (2011) A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 31(3): 528-535.
5. Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, et al. (2002) Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 33(12): 2858-2864.
6. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, et al. (2004) Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 24(4): 733-738.
7. Manning MW, Cassis LA, Daugherty A, (2003) Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 23 (3): 483-488.
8. Teixeira LR, Wu W, Chang DS, Light RW, (2002) The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits. Chest. 121(1): 216-219.
9. Chen WQ, Zhang L, Liu YF, Chen L, Ji XP, et al. (2007) Prediction of atherosclerotic plaque ruptures with high-frequency ultrasound imaging and serum inflammatory markers. Am J Physiol Heart Circ Physiol 293 (5): H2836-H2844.
10. Zhang L, Liu Y, Lu XT, Wu YL, Zhang C, et al. (2009) Chinese herbal medicine Tongxinluo dose-dependently enhances stability of vulnerable plaques: A comparison with a high-dose simvastatin therapy. Am J Physiol Heart Circ Physiol. 297 (6): H 2004-2014.
11. Axisa B, Naylor AR, Bell PR, Thompson MM, (2000) Simple and reliable method of doxycycline determination in human plasma and biological tissues. J Chromatogr B Biomed Sci Appl. 744 (2): 359-365.
12. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, et al. (1998) Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 18 (3): 369-378.
13. Williams H, Johnson JL, Carson KG, Jackson CL, (2002) Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 22 (5): 788-792.
14. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25 (4): 402-408.
15. Kim YS, Han CY, Kim SW, Kim JH, Lee SK, et al. (2001) The orphan nuclear receptor small heterodimer partner as a novel coregulator of nuclear factor-kappa b in oxidized low density lipoprotein-treated macrophage cell line RAW 264.7. J Biol Chem. 276(36): 33736-40.
16. Liu J, Xiong W, Baca-Regen L, Nagase H, Baxter BT, (2003) Mechanismof inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg. 38(6): 1376-83.
17. Matsumoto M, Einhaus D, Gold ES, Aderem A, (2004) Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J Immunol. 172(12): 7377-84.
18. Selvendiran K, Kuppusamy ML, Bratasz A, Tong L, Rivera BK, et al. (2009) Inhibition of vascular smooth-muscle cell proliferation and arterial restenosis by HO-3867, a novel synthetic curcuminoid, through up-regulation of PTEN expression. J Pharmacol Exp Ther. 329(3): 959-66.
19. Shapira L, Soskolne WA, Houri Y, Barak V, Halabi A, et al. (1996) Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect Immun. 64 (3): 825-828.
20. Kirkwood KL, Golub LM, Bradford PG, (1999) Non-antimicrobial and antimicrobial tetracyclines inhibit IL-6 expression in murine osteoblasts. Ann NY Acad. Sci. 878: 667-670.
21. Sheth RA, Maricevich M, Mahmood U, (2010) In vivo optical molecular imaging of matrix metalloproteinase activity in abdominal aortic aneurysms correlates with treatment effects on growth rate. Atherosclerosis. 2010 212(1): 181-187.
22. Ohshima S, Fujimoto S, Petrov A, Nakagami H, Haider N, et al. (2010) Effect of an antimicrobial agent on atherosclerotic plaques: Assessment of metalloproteinase activity by molecular imaging. J Am Coll Cardiol. 55 (12): 1240-1249.
23. Prescott MF, Sawyer WK, Von Linden-Reed J, Jeune M, Chou M, et al. (1999) Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Ann N Y Acad Sci. 878: 179-190.
24. Zhong L, Chen WQ, Ji XP, Zhang M, Zhao YX, et al. (2008) Dominant-negative mutation of monocyte chemoattractant protein-1 prevents vulnerable plaques from rupture in rabbits independent of serum lipid levels. J Cell Mol Med. 12 (6A): 2362-2371.